Lenacapavir deal lowers HIV treatment cost in over 100 countries

A new, twice-yearly HIV prevention injection, Lenacapavir, will be available at a significantly reduced cost in over 100 low-income countries by 2027. This landmark deal, brokered by the Clinton Foundation, will slash the annual cost from $28,000 to $40 per person, potentially providing access to millions. Lenacapavir offers a long-acting alternative to daily pills, aiming to reduce new infections and improve treatment adherence in vulnerable populations globally.